Evra

Amneal Receives Approval for Generic Version of Ortho Evra®

Retrieved on: 
Friday, February 26, 2021

In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.

Key Points: 
  • In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.
  • Amneals Norelgestromin and Ethinyl Estradiol Transdermal System is the generic version of the reference listed drug (RLD) Ortho Evra and will be marketed under the proprietary name Zafemy.
  • Todays approval is a significant milestone for patients and our company, said Chirag and Chintu Patel, Co-Chief Executive Officers.
  • Xulane is the only other equivalent to Ortho Evra currently available on the market.

GeoPhy Introduces Evra, a Property Valuation Platform Powered by the First AVM for Commercial Real Estate

Retrieved on: 
Wednesday, June 19, 2019

GeoPhy, one of the fastest growing companies in commercial real estate technology, has launched Evra, a new AI-powered valuation platform.

Key Points: 
  • GeoPhy, one of the fastest growing companies in commercial real estate technology, has launched Evra, a new AI-powered valuation platform.
  • Using Evra, commercial real estate investors, lenders, and researchers can now seamlessly access GeoPhys automated valuation model (AVM) the first AVM to provide accurate, transparent valuations for U.S. multifamily properties in an instant.
  • The Evra platform also exposes the following structural features that drive the GeoPhy AVM property value:
    Value drivers.
  • Co-headquartered in Delft, the Netherlands and New York City, GeoPhys machine learning algorithms power the most accurate AVM for commercial real estate.